NYSE:MRKPharmaceuticals
Merck (MRK) Valuation in Focus After FDA Breakthrough, Pipeline Advances, and New Cost-Cutting Plans
If you have been eyeing Merck (MRK) lately, the buzz this month might feel especially relevant. After months of anticipation, the company delivered a series of pipeline updates, with some results positive and others less so. Most recently, Merck secured an FDA Breakthrough Therapy Designation for ifinatamab deruxtecan in lung cancer, initiated new studies in breast cancer, and advanced several cardiovascular programs. At the same time, Merck announced a far-reaching cost reduction plan with...